Insmed Q1 revenue $306M, BRINSUPRI $207.9M (44% QoQ); reiterates FY guidance

INSMED Inc

2026-Q1 EPS reported -$0.76 revenue$305,964,000

Total Q1 2026 revenue $306.0M vs $92.8M YoY; BRINSUPRI contributed $207.9M (+44% vs Q4 2025).
Net loss narrowed to $163.6M ($0.76/sh) from $256.6M ($1.42/sh); cash & securities $1.2B.
FY 2026 guidance reaffirmed: BRINSUPRI revenue >=$1B, ARIKAYCE $450-470M.
Phase 3b ENCORE (ARIKAYCE in MAC) met primary and all multiplicity-controlled endpoints; sNDA H2 2026.
BRINSUPRI received UK marketing authorization; Phase 3 TPIP PAH study initiated in April 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSMED Inc reported the first quarter ended March 31, 2026 results: revenue $306.0 Million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $306.0 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-26-019430

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.